Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 10,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilead Sciences Stock Up 1.5%

GILD stock traded up $1.69 during trading hours on Friday, hitting $112.15. The company's stock had a trading volume of 1,957,126 shares, compared to its average volume of 7,730,579. The stock has a 50 day moving average price of $105.36 and a two-hundred day moving average price of $101.30. Gilead Sciences, Inc. has a 12 month low of $62.69 and a 12 month high of $119.96. The company has a market capitalization of $139.51 billion, a PE ratio of 303.22, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.32) earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Bridgewater Associates LP boosted its holdings in shares of Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after buying an additional 253,994 shares during the period. McAdam LLC boosted its holdings in Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after acquiring an additional 3,627 shares during the period. Nissay Asset Management Corp Japan ADV grew its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the last quarter. Clear Creek Financial Management LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $1,173,000. Finally, Jennison Associates LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $87,163,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. BMO Capital Markets upped their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald assumed coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.